Hartshorne Health LLC | DBA: HarleyMeds November 2026
1. General Consent & Telehealth
Purpose and scope
This combined consent explains telehealth care and the potential benefits, risks, limitations, alternatives, and responsibilities associated with the treatment categories described below. It supplements, and does not replace, a discussion with a licensed healthcare provider. The specific medication, dose, route, and treatment plan will be determined by the prescribing provider and identified in the patient’s treatment plan and prescription label. Consent does not guarantee that a medication will be prescribed.
Telehealth services and limitations
Telehealth uses electronic communications to exchange health records, intake information, laboratory results, images, and audio or video communications. Services may include medical evaluation, Good Faith Exam where applicable, eligibility and clearance assessments, diagnosis, consultation, prescriptions when clinically appropriate, referrals, and follow-up recommendations. A telehealth provider may determine that an in-person examination or additional testing is needed. Telehealth cannot provide a physical examination in all circumstances and is not a replacement for local primary care.
Telehealth may involve a separate treating provider or participating clinic. Any treating provider remains responsible for an independent assessment and procedure-specific consent when required.
Technology, privacy, and emergency care
Telehealth may be delayed or interrupted by technical problems, poor-quality transmissions, provider availability, or equipment failures. Electronic safeguards are intended to protect health information, but no system is completely free from privacy or security risks. Healthcare communications and records are handled subject to applicable privacy laws, including HIPAA where applicable.
TELEHEALTH IS NOT AN EMERGENCY SERVICE. For a medical emergency, call 911 or go to the nearest emergency department. Do not rely on a portal message, email, or telehealth appointment for emergency response.
Shared disclosures for all treatment categories
I understand that treatment is voluntary; I may decline treatment and discuss alternatives, including no treatment. Individual responses vary and results are not guaranteed. Medical treatment can involve known and unknown risks, and the provider may modify, withhold, or discontinue treatment based on medical judgment, safety, eligibility, or medication availability.
Some treatments, doses, routes, or indications described below may be off-label. Off-label prescribing does not mean FDA approval for that particular use. Where compounded medications are prescribed, they are not FDA-approved products and have not undergone FDA premarket review for safety, effectiveness, quality, or bioequivalence. Compounded products may differ in potency, concentration, stability, and sterility; availability and legal eligibility can change.
I agree to provide complete and accurate medical history, allergies, medications, supplements, relevant substance use, pregnancy or breastfeeding status, and updates to my health. I agree to use only prescribed doses and routes, follow storage and administration instructions, attend recommended monitoring, and contact the care team about adverse effects or changes in health. I understand that a prescribing provider may require additional examination or testing.
2. Hormone Replacement Therapy (HRT / TRT)
About The Treatment
I voluntarily consent to receive hormone replacement therapy (HRT). HRT may include, but is not limited to: testosterone (injectable, topical, oral, pellet, or other forms); estrogen (oral, transdermal, injectable, or pellet); progesterone (oral, topical, or other forms); dehydroepiandrosterone (DHEA); and adjunct or ancillary hormone- modulating medications including anastrozole, enclomiphene, gonadorelin, and human chorionic gonadotropin (hCG), or other hormone-modulating therapies as clinically recommended. The specific medication(s), dose, and route prescribed to me will be identified in my treatment plan and on my prescription label. Hormone replacement therapy involves altering endogenous hormone levels and may affect multiple organ systems, including cardiovascular, endocrine, reproductive, hepatic, metabolic, hematologic, neurologic, and psychological systems.
Testosterone Therapy Disclosure
If I am prescribed testosterone therapy, I understand that testosterone may increase red blood cell production (polycythemia), which may increase the risk of blood clots, stroke, heart attack, or other cardiovascular events. Monitoring of hemoglobin and hematocrit may be recommended. Testosterone therapy may affect lipid levels, blood pressure, liver enzymes, mood, sleep patterns, fertility, and prostate health. Testosterone therapy may suppress natural testosterone production and may reduce sperm production and fertility; this suppression may be temporary or prolonged. Fertility preservation strategies may be necessary if future fertility is desired. Potential risks of testosterone therapy include, but are not limited to, acne, oily skin, fluid retention, increased red blood cell count, mood changes, irritability, sleep apnea exacerbation, prostate enlargement, changes in libido, gynecomastia, and cardiovascular risk. Long-term cardiovascular risk related to testosterone therapy remains an area of ongoing research and medical debate.
Estrogen & Progesterone Therapy Disclosure
If I am prescribed estrogen and/or progesterone therapy, I understand that hormone therapy may increase the risk of blood clots (deep vein thrombosis or pulmonary embolism), stroke, and cardiovascular events, particularly in individuals with risk factors such as smoking, obesity, hypertension, or clotting disorders. Estrogen therapy may increase the risk of certain hormone-sensitive cancers, including breast cancer and endometrial cancer. Progesterone is often prescribed with estrogen in women with an intact uterus to reduce the risk of endometrial hyperplasia or cancer, but risk cannot be eliminated entirely. Estrogen therapy may also increase the risk of gallbladder disease, fluid retention, migraine changes, breast tenderness, mood changes, and abnormal uterine bleeding, and may influence lipid levels, liver function, and clotting pathways.
Adjunct & Ancillary Medications Disclosure
ANASTROZOLE is an aromatase inhibitor that reduces the conversion of testosterone to estradiol. It is prescribed off-label, most commonly to manage elevated estradiol during testosterone therapy. Risks include, but are not limited to, joint aches and stiffness, mood changes, fatigue, hot flashes, lipid changes, and, particularly with prolonged use or over-suppression of estradiol, decreased bone mineral density, low libido, and worsened mood or energy. Estradiol should not be suppressed below healthy levels, and laboratory monitoring is recommended. ENCLOMIPHENE is a selective estrogen receptor modulator that stimulates the body’s own production of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which may raise natural testosterone while preserving fertility. It is prescribed off-label and is typically compounded. Risks include, but are not limited to, headache, nausea, hot flashes, mood changes or irritability, and, uncommonly, visual disturbances (blurred vision, floaters, or spots). I agree to stop the medication and notify my provider immediately if visual symptoms occur. Rare risks include blood clots. GONADORELIN is a gonadotropin-releasing hormone analog used off- label, typically alongside testosterone therapy, to support the body’s natural signaling to the testes and help maintain testicular function. It is typically compounded. Risks include, but are not limited to, injection-site reactions, headache, flushing, and nausea, and its effectiveness may depend on dosing frequency. HUMAN CHORIONIC GONADOTROPIN (hCG) mimics LH and stimulates the testes to produce testosterone, and is used off-label to maintain testicular volume, natural hormone production, and fertility during testosterone therapy. Risks include, but are not limited to, injection-site reactions, acne, fluid retention, mood changes, and gynecomastia or estrogen-related effects (hCG increases estradiol production). hCG is regulated as a biologic, and the availability of compounded hCG may change based on current FDA policy; my provider may substitute an alternative (such as gonadorelin) if availability changes.
General Hormone Risks
Hormone therapy may affect mood, anxiety, irritability, sleep patterns, libido, and energy levels; hormonal adjustments may cause temporary or persistent emotional changes. Hormone therapy may also influence insulin sensitivity, thyroid function, and metabolic parameters. Individuals with a history of breast cancer, prostate cancer, clotting disorders, uncontrolled cardiovascular disease, liver disease, severe hyperlipidemia, or certain endocrine disorders may not be appropriate candidates for therapy. I confirm that I have disclosed my complete medical history. Pregnancy and breastfeeding are contraindications to this therapy. I confirm that I am not pregnant and will notify my provider immediately if pregnancy occurs.
Administration Methods
Hormones may be administered via injection, topical cream, patch, pellet implantation, oral capsule, or other delivery methods, and each route carries specific risks. Pellet insertion is an in-person minor procedure and carries risks of infection, extrusion, bleeding, and scarring. Injectable therapy carries risks of injection-site reactions or improper administration if self- injected.
Alternatives To Treatment
Alternatives include: no treatment; lifestyle modification (nutrition, exercise, sleep, stress management); FDA- approved conventional hormone products at standard dosing; and non-hormonal therapies for specific symptoms. The benefits, risks, and limitations of reasonable alternatives have been discussed with me to my satisfaction.
Outcomes & Expectations
Response to hormone therapy varies significantly between individuals. Symptom improvement is not guaranteed, and therapy may require dose adjustments, modification, or discontinuation. Some uses of hormone therapy may be considered elective, optimization-based, or not medically necessary by certain providers or insurers.
3. GLP-1 / GIP Medication Therapy
About The Treatment & Potential Benefits
I voluntarily consent to glucagon-like peptide-1 (GLP-1) and/or dual GIP/GLP-1 receptor agonist therapy for medically supervised weight management or metabolic health. Medications may include semaglutide, tirzepatide, liraglutide, or similar agents, in branded (Wegovy®, Ozempic®, Zepbound®, Mounjaro®, Saxenda®) or compounded formulations, given by subcutaneous injection (or oral formulation where applicable). My medication, dose, and titration schedule will be in my treatment plan and on my prescription label. These medications mimic incretin hormones: they slow stomach emptying, reduce appetite and food intake, and improve insulin response. They are meant to be used with reduced-calorie nutrition and increased physical activity. Weight loss varies, develops gradually with dose titration, and WEIGHT REGAIN IS COMMON IF THE MEDICATION IS STOPPED without sustained lifestyle change. Muscle loss may accompany weight loss; adequate protein and resistance exercise are recommended. Potential benefits include weight loss, improved blood sugar control, reduced cardiovascular risk, and better metabolic health. These benefits were shown in studies of FDA-approved products, are not established for compounded products, and are not guaranteed.
Eligibility, Bmi & Off-Label Use
FDA-approved GLP-1 / GIP medications for chronic weight management are indicated for adults with a body mass index (BMI) of 30 kg/m2 or greater, or 27 kg/m2 or greater with at least one weight-related condition (such as high blood pressure, type 2 diabetes, high cholesterol, or sleep apnea). If my BMI is outside this range, my treatment is off-label. At a lower BMI there is a greater chance of losing more weight than is healthy, becoming underweight, losing muscle and bone, and developing nutritional deficiencies, and of worsening or triggering disordered eating. BMI does not measure body composition and is one factor in my provider’s decision; my provider may decline treatment at any BMI. Some GLP-1 medications are FDA-approved for type 2 diabetes and prescribed off-label for weight management; specific doses, combinations, or compounded formulations may also be off-label. Off-label prescribing is legal and common when based on a licensed provider’s clinical judgment, but it is not FDA approval for that use, and long-term safety data may be limited or evolving. My provider relies on my self-reported height, weight, and BMI to decide whether treatment is safe and to set my dose, and I attest that my reported height, weight, and BMI are accurate and current, and I agree to update them when asked. Photos are not routinely required, but my provider may ask for verification (a scale photo or video, full-body photos, a
clinic weigh-in, or outside records); I consent to provide it if asked, and photos will be stored in my medical record. I will not misstate my height, weight, or medical conditions to qualify. My provider may reduce or stop treatment if I reach my goal weight, lose weight, become underweight, or if my information cannot be verified.
Additives, Vitamins & Other Ingredients
My compounded medication may contain added vitamins, amino acids, or other ingredients (“additives”) and inactive ingredients (such as preservatives like benzyl alcohol, phenol, or metacresol, buffers, and stabilizers, which can cause irritation or allergic reactions). Which additives are included, and in what amounts, depends on the formulation and pharmacy and may differ between refills or batches. My label and pharmacy documentation list my ingredients, and I may ask for the complete list at any time. Additives have not been proven to increase weight loss, and the FDA has not evaluated these combinations. They carry their own risks in addition to those of the GLP-1 / GIP medication. • Vitamin B12 (cyanocobalamin or methylcobalamin): Injection-site pain, redness, or itching; headache; dizziness; mild diarrhea; rash. Rarely, serious allergic reaction including anaphylaxis. Cyanocobalamin contains cobalt; avoid with known allergy to cobalt or cobalamins. Avoid in Leber’s hereditary optic neuropathy; may be less suitable in significant kidney disease. Rarely, low potassium or blood count changes. • Vitamin B6 (pyridoxine): Usually well tolerated at low doses. Prolonged high total intake (all injections and supplements combined) can cause nerve damage (numbness, tingling, or burning in the hands or feet) and sun sensitivity. May reduce the effect of levodopa (without carbidopa) and lower blood levels of phenytoin and phenobarbital. • Vitamin B3 (niacinamide or niacin): Nausea, stomach upset, headache, dizziness, and, especially with niacin, flushing, itching, or low blood pressure. High doses may raise liver enzymes, cause liver injury, and affect blood sugar. Caution with liver disease, active stomach ulcer, gout, or low blood pressure, and with blood pressure, diabetes, or cholesterol medications. Niacinamide may raise levels of some drugs (e.g., carbamazepine). • Glycine: Generally well tolerated. May cause nausea, soft stools, abdominal discomfort, or drowsiness. Caution with significant kidney or liver disease. May reduce the effectiveness of clozapine. Not studied with these medications or for weight loss. • Other possible additives (L-carnitine, methionine, inositol, choline, other B vitamins, taurine, biotin): Possible nausea, stomach upset, diarrhea, headache, dizziness, or allergic reaction; some are not well studied in injectable form or with GLP-1 / GIP medications. Biotin can interfere with certain lab tests (including thyroid and cardiac troponin); I will tell any lab or clinician if I take biotin. I will tell my provider about all allergies (including cobalt, vitamins, preservatives, or any ingredient on my label) and every vitamin, supplement, and medication I take, and will not add high-dose B vitamins, niacin, or other supplements without asking. I will check the ingredient list on every shipment and report changes. If I develop a rash, swelling, trouble breathing, numbness or tingling, or any vision change after an injection, I will stop and contact my provider, and seek emergency care if severe. I may request a formulation without additives or a branded FDA-approved product at any time.
Optional Add-On: Ondansetron (Zofran®) For Nausea
OPTIONAL. Ondansetron (Zofran®) is a prescription anti-nausea medication my provider may offer, separately from my GLP-1 / GIP medication, if nausea does not improve. I am not required to accept it, declining will not affect my GLP-1 / GIP treatment, and I can receive it only if my provider prescribes it. Ondansetron (Zofran®): Common: headache, constipation, fatigue, dizziness. Serious: heart rhythm changes (QT prolongation, including torsades de pointes), especially with low potassium or magnesium, heart failure, slow heart rate, family history of long QT syndrome, or other QT-prolonging medicines (some antiarrhythmics, antipsychotics, antidepressants, macrolide or fluoroquinolone antibiotics); serotonin syndrome with serotonergic medicines (SSRIs, SNRIs, MAOIs, tramadol, triptans); allergic reaction. It may mask symptoms of a bowel blockage or stomach distension, which matters with GLP-1 / GIP medicines, so I will seek care for worsening abdominal pain or swelling, persistent vomiting, or inability to pass stool or gas. Do not use with congenital long QT syndrome or apomorphine. Lower doses are needed in severe liver disease. Dissolving tablets may contain phenylalanine. Tell my provider if I am or may be pregnant. I will take it only as prescribed and contact my provider promptly for fainting, a racing or irregular heartbeat, severe dizziness, agitation, fever, muscle rigidity, severe diarrhea, or allergic reaction (911 if severe). I will tell my provider about any heart condition, family history of sudden cardiac death or long QT syndrome, and all my medications. By accepting ondansetron from my provider, I confirm that I have read these risks.
Important Safety Information: Thyroid Tumor Warning
GLP-1 and GIP/GLP-1 medications caused thyroid C-cell tumors in rodent studies. It is unknown whether they cause medullary thyroid carcinoma (MTC) in humans. THESE MEDICATIONS MUST NOT BE USED by individuals with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). I agree to report promptly any neck mass or lump, difficulty swallowing, persistent hoarseness, or shortness of breath. I confirm that I have no personal or family history of MTC or MEN 2.
Important Safety Information: Sudden Vision Loss (Naion)
NEW FDA SAFETY COMMUNICATION (NOVEMBER 9, 2026). The FDA is requiring all GLP-1 receptor agonist medications, including semaglutide, tirzepatide, and liraglutide, to add a warning about a potential increased risk of non- arteritic anterior ischemic optic neuropathy (NAION), a rare eye condition that can cause sudden, painless vision loss in one eye, including permanent vision loss. NAION occurs when blood flow to the front of the optic nerve drops, damaging the nerve that carries visual information to the brain. The FDA describes the risk as potential and rare; a cause-and-effect relationship has not been established and the mechanism is not fully understood. Cases have been reported with every marketed GLP-1 medication, and European regulators concluded in 2025 that NAION is a very rare side effect of semaglutide, affecting up to 1 in 10,000 people. Because compounded products contain the same active ingredients, the risk may apply to them as well. Symptoms (which may be noticed upon waking): sudden, painless vision loss or decreased vision in one eye; blurred or missing portions of vision such as blind spots or tunnel vision; distorted or washed-out colors; reduced central sharpness. If I notice any of these, I will contact my provider right away, seek urgent evaluation by an eye specialist, and hold my next dose until evaluated. If NAION is diagnosed, my provider will likely recommend stopping the medication unless the benefits clearly outweigh the risk, and NAION in one eye increases the chance of it in the other. Known risk factors include diabetes, high blood pressure, sleep apnea, smoking, anemia, and kidney disease. I will tell my provider about any history of NAION, optic nerve disease, or other eye or vision problems.
Risks & Side Effects
Common side effects, most frequent during dose increases and often improving with time, include nausea, vomiting, diarrhea, constipation, abdominal pain, bloating, belching, heartburn or reflux, decreased appetite, fatigue, headache, dizziness, and injection-site reactions. Other reported effects include increased resting heart rate, hair thinning or hair loss, low blood pressure or lightheadedness (especially with dehydration), changes in taste, and facial or body volume loss and skin laxity with rapid weight loss. Rapid weight loss may reduce muscle and bone mass and cause nutritional deficiencies if protein, vitamin, and mineral intake is inadequate. Although uncommon, these medications can result in emergency room visits, hospitalization, permanent harm, or even death. Serious risks include, but are not limited to: pancreatitis (severe, persistent abdominal pain that may radiate to the back; stop the medication and seek immediate care); gallbladder disease, including gallstones and cholecystitis (risk increases with rapid weight loss); dehydration and kidney injury from vomiting or diarrhea; severe slowing of stomach emptying (gastroparesis-like symptoms); bowel obstruction (ileus); hypoglycemia, particularly with insulin or sulfonylureas; worsening diabetic retinopathy (semaglutide, in patients with diabetes); sudden vision loss from NAION, which may be permanent; aspiration during anesthesia or sedation; allergic reactions, rarely including anaphylaxis; and overdose from dosing errors. Mood. In January 2026 the FDA reported that its review found no increased risk of suicidal thoughts or behavior with GLP-1 medications and asked manufacturers to remove that warning from weight-loss labels. Mood changes can still occur with any medication or major change in weight and eating. I will tell my provider promptly about new or worsening depression, anxiety, or unusual changes in mood or behavior. If I am thinking of harming myself, I will call or text 988 or call 911 immediately.
When To Seek Emergency Care
I will call 911 or go to the nearest emergency room, and notify my provider, for: severe or persistent abdominal pain; repeated vomiting or inability to keep fluids down; swelling of the face, lips, tongue, or throat, trouble breathing, or hives; sudden loss or change of vision; fainting, confusion, or severe dizziness; signs of low blood sugar (shakiness, sweating, confusion); yellowing of the skin or eyes; a neck lump or trouble swallowing; or symptoms after taking more medication than prescribed. For a suspected overdose I will also call Poison Control at 1-800-222-1222; because these medications stay in the body about a week, overdose symptoms may last several days. Side effects may be reported to FDA MedWatch at www.fda.gov/medwatch or 1-800-332-1088.
Safe Use & Dosing (Self-Administration)
DOSING ERRORS ARE A KNOWN SERIOUS RISK. The FDA has received reports of hospitalizations from patients drawing up 5 to 20 times their intended dose from compounded multiple-dose vials, often through confusion between milligrams (mg), milliliters (mL), and syringe “units.” • I will take only the dose, schedule, and syringe or device my provider prescribes, will not increase, decrease, skip, split, or change my dose or titration on my own, and will never take extra to lose weight faster. • I will store and handle it as instructed, use a new sterile needle and syringe each time, rotate sites, dispose of sharps in an FDA-cleared container, and never share my medication, needles, or syringes. • If I miss a dose I will follow my provider’s written instructions and not double up. If I stop for more than a short period, I will contact my provider before restarting, because my dose may need to be lowered.
Contraindications & Precautions
GLP-1 / GIP therapy may not be appropriate if I have conditions including, but not limited to: • Personal or family history of medullary thyroid carcinoma (MTC) or MEN 2. • History of pancreatitis (requires provider evaluation and caution); severe gastrointestinal disease, including gastroparesis. • Pregnancy, planned pregnancy, or breastfeeding (see below). • Type 1 diabetes or history of diabetic ketoacidosis (these medications are not insulin substitutes). • Prior severe hypersensitivity to the medication or its components, including cobalt or cobalamins, B vitamins, glycine, or preservatives. • Active gallbladder disease without provider clearance. • Prior NAION or other optic nerve disease, including Leber’s hereditary optic neuropathy (relevant to B12) (requires provider evaluation). • Conditions needing evaluation and caution: kidney or liver disease, diabetic retinopathy, cardiovascular disease, history of eating disorder, and use of other weight-loss or diabetes medications.
Drug Interactions, Anesthesia & Procedures
GLP-1 medications may increase hypoglycemia risk with insulin or sulfonylureas (dose adjustments may be required), may slow absorption of oral medications, and, for tirzepatide, may reduce the effectiveness of oral contraceptive pills (see below). Because they slow stomach emptying, they may increase the risk of regurgitation and aspiration during sedation or general anesthesia. I will tell any surgeon, anesthesiologist, endoscopist, or proceduralist that I take a GLP-1 medication and follow their and my provider’s instructions about holding it before a procedure. I will disclose all prescription and over-the-counter medications, supplements, and recreational substances, and any history of eating disorder, which may make weight-loss medication inappropriate.
Pregnancy, Contraception & Breastfeeding
These medications may pose a risk to a developing fetus. Tirzepatide can reduce the effectiveness of oral contraceptive pills, so the pill alone is not enough. If I take tirzepatide and use oral contraception, I will continue it and add a barrier method (such as condoms) for four weeks after I start and four weeks after each dose increase, or switch to a non-oral method (such as an IUD or implant) before starting. When I stop the medication, I will continue effective contraception for at least two months, or as my provider instructs, before trying to become pregnant. I will tell my provider immediately if I am or may become pregnant and will stop the medication as directed. It is not known whether these medications are safe during breastfeeding; if I am breastfeeding, I will discuss safer weight-management options with my provider.
Monitoring & My Responsibilities
My provider may require check-ins, weight and blood pressure reporting, lab tests, or an eye exam, and may adjust, pause, or stop treatment at any time for safety. I agree to complete follow-ups, report side effects and changes in my health or medications promptly, and continue healthy eating, hydration, and physical activity. Treatment may be stopped if I do not follow instructions or if my information proves inaccurate or incomplete.
Truthfulness & Accuracy Of Information
I attest that all information and photos I have provided to Hartshorne Health LLC (doing business as HarleyMeds) and its providers are true, accurate, and complete; that I have not withheld or misstated any medical history (including personal or family history of thyroid cancer, MTC, or MEN 2; pancreatitis; eye conditions including NAION; eating disorders; diabetes; kidney, liver, or gallbladder disease; pregnancy or breastfeeding status; and allergies to any vitamin, additive, or preservative) or any medication, supplement, or substance I use; that I am the person on my patient account and my measurements are my own; and that I will promptly report changes. I understand that inaccurate or incomplete information may seriously harm me and may end my treatment. To the fullest extent permitted by law, I accept responsibility for omissions or inaccuracies, whether intentional or not, and will not hold my provider or Hartshorne Health LLC (doing business as HarleyMeds) responsible for harm resulting from information I omitted or misstated.
Alternatives, No Guarantee & Voluntary Participation
Alternatives include no treatment; lifestyle modification alone (nutrition, activity, sleep, behavioral support); other FDA- approved weight-management medications, including branded GLP-1 / GIP products; a compounded formulation without additives; and bariatric surgery. These have been discussed with me to my satisfaction. Weight loss varies significantly and is not guaranteed, and therapy may require dose adjustment, modification, or discontinuation. Participation is voluntary: I may decline or discontinue at any time. All medical treatments carry known and unknown risks, and I voluntarily assume all known and unknown risks of GLP-1 / GIP therapy, including risks of off-label use, lower-BMI treatment, compounded formulations, additives, and self-administration. I am at least 18 years old and legally competent to consent.
4. Peptide Therapy
About The Treatment
I voluntarily consent to receive compounded peptide therapy. Peptides are biologically active amino acid chains that function as signaling molecules in the body and may influence hormonal pathways, growth hormone and insulin-like growth factor (IGF-1) activity, immune function, inflammatory pathways, vascular tone, libido, mitochondrial activity, tissue repair, angiogenesis, metabolism, and other cellular processes. Categories of peptides that may be prescribed include: growth hormone–releasing peptides and secretagogues (including sermorelin, ipamorelin, CJC-1295, tesamorelin, and related compounds); regenerative and tissue- repair peptides (including BPC-157, TB-500/thymosin beta-4, GHK-Cu, and similar agents); mitochondrial and metabolic peptides (including MOTS-c); longevity-associated peptides (including epitalon); immune-modulating peptides (including thymosin alpha-1); sexual health peptides (including PT-141/bremelanotide); sleep- support peptides (including DSIP); and cognitive and mood-support peptides (including semax and selank). The specific peptide(s), dose, and route prescribed to me will be identified in my treatment plan and on my prescription label, and this consent applies to the peptide therapy so prescribed, including reasonable modifications and substitutions within the same category.
Regulatory Status Of Peptides
Many peptide therapies are prescribed off-label and are not approved by the FDA for the specific purposes for which they may be recommended. Off-label prescribing is legally permitted but does not constitute FDA approval for the intended use, and long-term safety data for certain peptides may be limited or evolving. The regulatory status of individual peptide ingredients changes over time: the FDA periodically re-categorizes which bulk substances are eligible for pharmacy compounding, and the availability of a specific peptide may depend on current FDA policy and the compliance decisions of the compounding pharmacy. My provider may modify, substitute, or discontinue a specific peptide if its regulatory status or availability changes, and I understand that no representation is made that any particular peptide is FDA-approved for my intended use.
Risks & Side Effects (All Peptides — Combined)
Peptide therapy may cause side effects including, but not limited to: injection-site pain, redness, swelling, bruising, infection, or abscess formation, as well as headache, dizziness, flushing, fatigue, edema or fluid retention, changes in blood sugar, hormonal changes, mood changes, anxiety, sleep disturbance, gastrointestinal symptoms, cardiovascular changes, and allergic reactions — severe allergic reactions, though rare, may require emergency treatment. Human safety data for many peptides is limited, and long-term effects may be unknown. Depending on the peptide(s) prescribed, additional risks may include, but are not limited to: water retention or swelling of the hands and feet; joint aches and stiffness; tingling or numbness of the hands (carpal tunnel–like symptoms); increased hunger; elevated blood sugar or reduced insulin sensitivity, or symptoms of low blood sugar, particularly in individuals taking diabetes medications; elevated IGF-1 levels, which may theoretically influence cellular proliferation, including the growth of undiagnosed tumors; significant nausea and possible vomiting, and — with repeated use of PT-141 — potentially permanent darkening of the skin or gums (focal hyperpigmentation) and temporary changes in blood pressure and heart rate after each dose; drowsiness or sedation and additive effects with alcohol or sleep medications (I will not drive or operate machinery until effects are known); vivid dreams or sleep disturbance; restlessness, irritability, or anxiety; nasal irritation with intranasal use; local skin irritation or copper- sensitivity reactions; mild flu-like symptoms or muscle aches; and unpredictable changes in immune activity, including the theoretical possibility of triggering or worsening autoimmune symptoms.
Contraindications (All Peptides — Combined)
Peptide therapy may not be appropriate in the presence of conditions including, but not limited to: pregnancy, planned pregnancy, or breastfeeding; known hypersensitivity to the prescribed peptide or formulation components; active malignancy, recent cancer history, or undiagnosed masses without oncologic clearance; uncontrolled diabetes or proliferative diabetic retinopathy; active pituitary disease or pituitary tumor; disorders of copper metabolism (e.g., Wilson’s disease, for copper-containing peptides); use of insulin or other glucose- lowering medications without provider review; organ transplant or use of immunosuppressant medications, or active autoimmune disease, without provider review; uncontrolled hypertension or significant or unstable cardiovascular disease; severe kidney or liver disease without provider clearance; use of sedatives, hypnotics, or other central nervous system depressants, or untreated sleep apnea, without provider review; and unstable psychiatric conditions or seizure disorder without provider clearance. I agree to discuss any of these that apply to me with my provider before treatment.
Health Disclosure
I confirm that I have disclosed any history of cancer, abnormal biopsies, autoimmune disease, immune suppression, cardiovascular disease, neurologic disorders, psychiatric conditions, endocrine disorders, kidney disease, liver disease, clotting disorders, or other significant medical conditions. Peptide therapy may interact with other medications, hormones, or supplements; I agree to disclose all medications and substances I am taking and to notify my provider of any changes. Peptide therapy may influence reproductive hormones. The safety of peptide therapy during pregnancy or breastfeeding is not established. I confirm that I am not pregnant and understand that pregnancy and breastfeeding are contraindications.
Alternatives To Treatment
Alternatives include: no treatment; lifestyle interventions (nutrition, exercise, sleep optimization); FDA-approved medications for the relevant indication where available; and other conventional medical care. Peptide therapy may be considered elective or investigational in certain contexts and may not be universally accepted by all medical professionals.
